Repligen (RGEN) 2024 Wells Fargo Healthcare Conference summary

Leadership and strategic direction

• Newly appointed CEO brings 27+ years of industry experience and emphasizes the company's role as an innovation engine with a broad product portfolio.

• Focus on breakthrough innovation and complementary acquisitions, with recent examples like Metenova and Tantti to enhance technology and market reach.

• Key account management program expanded, now covering 21 accounts, aiming to drive cross-selling and deeper customer relationships.

• M&A strategy remains focused on unique, value-adding assets, with openness to larger deals as the company grows.

Market environment and industry trends

• Bioprocessing industry headwinds from COVID, inventory overhang, and China are expected to ease by year-end, with most destocking behind.

• China market faces structural changes: local competition rising, government focus shifting to innovation, and reimbursement pressures.

• Funding for small biotech rebounded in early 2024, positively impacting both small biotech and CDMO segments.

• Pharma segment shows strong CapEx recovery, especially in Europe and the US, while Asia remains a smaller contributor.

Segment performance and growth drivers

• Filtration franchise leads with 20% order growth, driven by proprietary ATF technology and strong market demand for process intensification.

• Chromatography's Opus columns show growth, though overall segment numbers are affected by reduced resin sales; focus remains on differentiated offerings.

• Fluid management segment still recovering from post-COVID destocking, with some inventory overhang expected to persist.

• New modalities business is broad-based, with over 20 accounts above $1 million in sales and strong order growth in Q2.

• Equipment segment rebounded in Q2, with innovation like the RS10 system and focus on PAT-enabled hardware for differentiation.